7.72
price up icon2.39%   0.18
after-market Dopo l'orario di chiusura: 7.72
loading
Precedente Chiudi:
$7.54
Aprire:
$7.53
Volume 24 ore:
102.14K
Relative Volume:
0.55
Capitalizzazione di mercato:
$160.58M
Reddito:
-
Utile/perdita netta:
$-117.17M
Rapporto P/E:
-5.8045
EPS:
-1.33
Flusso di cassa netto:
$-91.71M
1 W Prestazione:
-0.52%
1M Prestazione:
+2.52%
6M Prestazione:
-25.98%
1 anno Prestazione:
-17.10%
Intervallo 1D:
Value
$7.26
$7.7672
Intervallo di 1 settimana:
Value
$7.17
$8.07
Portata 52W:
Value
$6.38
$29.70

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name
Nome
Adverum Biotechnologies Inc
Name
Telefono
(650) 649-1004
Name
Indirizzo
100 CARDINAL WAY, REDWOOD CITY, CA
Name
Dipendente
121
Name
Cinguettio
@adverumbio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
ADVM's Discussions on Twitter

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2022-07-07 Aggiornamento Truist Hold → Buy
2021-07-23 Downgrade Cantor Fitzgerald Overweight → Neutral
2021-05-03 Downgrade SVB Leerink Outperform → Mkt Perform
2021-04-29 Downgrade Chardan Capital Markets Buy → Neutral
2021-04-29 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-04-29 Downgrade Truist Buy → Hold
2020-12-16 Iniziato UBS Neutral
2020-11-12 Aggiornamento Raymond James Underperform → Mkt Perform
2020-06-26 Downgrade Raymond James Mkt Perform → Underperform
2020-05-13 Iniziato RBC Capital Mkts Outperform
2020-05-05 Aggiornamento SunTrust Hold → Buy
2020-04-28 Iniziato Goldman Buy
2020-03-16 Iniziato SVB Leerink Outperform
2020-02-10 Aggiornamento Cantor Fitzgerald Neutral → Overweight
2020-02-10 Aggiornamento Chardan Capital Markets Neutral → Buy
2019-10-15 Reiterato Chardan Capital Markets Neutral
2019-09-13 Reiterato Chardan Capital Markets Neutral
2019-06-14 Ripresa Raymond James Mkt Perform
2018-11-02 Downgrade Raymond James Outperform → Mkt Perform
2018-11-02 Downgrade SunTrust Buy → Hold
2018-09-21 Iniziato Cantor Fitzgerald Overweight
2018-08-30 Iniziato SunTrust Buy
2018-02-15 Ripresa Piper Jaffray Overweight
2017-10-12 Iniziato Raymond James Outperform
Mostra tutto

Adverum Biotechnologies Inc Borsa (ADVM) Ultime notizie

pulisher
11:35 AM

Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $10.00 by Analysts at Royal Bank of Canada - MarketBeat

11:35 AM
pulisher
Nov 04, 2024

Adverum Biotechnologies Advances in Gene Therapy Development - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 04, 2024
pulisher
Nov 04, 2024

Adverum Biotechnologies: Q3 Earnings Snapshot - San Antonio Express-News

Nov 04, 2024
pulisher
Nov 04, 2024

Adverum Biotechnologies Reports Third Quarter 2024 - GlobeNewswire

Nov 04, 2024
pulisher
Nov 04, 2024

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate - The Bakersfield Californian

Nov 04, 2024
pulisher
Nov 04, 2024

Adverum Biotechnologies Reports Third Quarter 2024 Financial Results, Provides Corporate Highlights and Updates Anticipated Milestones - StockTitan

Nov 04, 2024
pulisher
Nov 04, 2024

Assenagon Asset Management S.A. Has $164,000 Stock Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat

Nov 04, 2024
pulisher
Oct 29, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Short Interest Update - MarketBeat

Oct 29, 2024
pulisher
Oct 22, 2024

Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - GlobeNewswire Inc.

Oct 22, 2024
pulisher
Oct 22, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Oct 22, 2024
pulisher
Oct 16, 2024

Adverum Biotechnologies names new chief commercial officer - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

Adverum Biotechnologies Appoints Jason L. Mitchell as Chief Commercial Officer as it Prepares to Initiate Pivotal Program - StockTitan

Oct 16, 2024
pulisher
Oct 13, 2024

Dimensional Fund Advisors LP Buys 196,884 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat

Oct 13, 2024
pulisher
Oct 11, 2024

Adverum Biotechnologies (ADVM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance

Oct 11, 2024
pulisher
Oct 08, 2024

Squarepoint Ops LLC Raises Holdings in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Shares Purchased by Marshall Wace LLP - MarketBeat

Oct 07, 2024
pulisher
Oct 03, 2024

ADVM Stock Sees Surge of Approximately 3.49% in Last Five Days - Knox Daily

Oct 03, 2024
pulisher
Oct 03, 2024

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic - Yahoo Finance

Oct 03, 2024
pulisher
Oct 02, 2024

Bet on 5 Top-Ranked Stocks With Rising P/E - Yahoo Finance

Oct 02, 2024
pulisher
Oct 01, 2024

Logos Global Management LP Sells 1,083,333 Shares of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat

Oct 01, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: Adverum Biotechnologies stock faces pivotal year amid trials - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

Mizuho Initiates Coverage of Adverum Biotechnologies (ADVM) with Buy Recommendation - MSN

Sep 27, 2024
pulisher
Sep 27, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives $28.17 Average Target Price from Analysts - MarketBeat

Sep 27, 2024
pulisher
Sep 24, 2024

(ADVM) Trading Advice - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Cuts Stake in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World

Sep 24, 2024
pulisher
Sep 19, 2024

Adverum Biotechnologies (NASDAQ:ADVM) Share Price Passes Below Two Hundred Day Moving Average of $9.52 - MarketBeat

Sep 19, 2024
pulisher
Sep 13, 2024

(ADVM) Investment Analysis - Stock Traders Daily

Sep 13, 2024
pulisher
Sep 05, 2024

Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 05, 2024
pulisher
Sep 04, 2024

Adverum Biotechnologies to Participate in Upcoming Fall Investor Conferences - ForexTV.com

Sep 04, 2024
pulisher
Sep 03, 2024

Wall Street Analysts See a 332.28% Upside in Adverum Biotechnologies (ADVM): Can the Stock Really Move This High? - Yahoo Finance

Sep 03, 2024
pulisher
Sep 02, 2024

Adverum Biotechnologies Inc (ADVM) rating initates by Oppenheimer - Knox Daily

Sep 02, 2024
pulisher
Sep 02, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 02, 2024
pulisher
Sep 02, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Increase in Short Interest - Defense World

Sep 02, 2024
pulisher
Aug 31, 2024

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Sees Significant Growth in Short Interest - MarketBeat

Aug 31, 2024
pulisher
Aug 28, 2024

Adverum Biotechnologies (NASDAQ:ADVM) Share Price Crosses Above Fifty Day Moving Average of $7.31 - Defense World

Aug 28, 2024
pulisher
Aug 28, 2024

Adverum Biotechnologies (NASDAQ:ADVM) Shares Pass Above 50-Day Moving Average of $7.31 - MarketBeat

Aug 28, 2024
pulisher
Aug 25, 2024

Adverum Biotechnologies, Inc. Appoints Eric G. Carter to its Board of Directors - Marketscreener.com

Aug 25, 2024
pulisher
Aug 21, 2024

The Potential Rise in the Price of Adverum Biotechnologies Inc (ADVM) following insiders activity - Knox Daily

Aug 21, 2024
pulisher
Aug 20, 2024

Assenagon Asset Management S.A. Boosts Stock Position in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) - MarketBeat

Aug 20, 2024
pulisher
Aug 19, 2024

Mizuho cuts Adverum Biotechnologies target to $20 from $22 By Investing.com - Investing.com Canada

Aug 19, 2024
pulisher
Aug 18, 2024

(ADVM) Long Term Investment Analysis - Stock Traders Daily

Aug 18, 2024
pulisher
Aug 17, 2024

FY2024 EPS Estimates for Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Boosted by Chardan Capital - Defense World

Aug 17, 2024
pulisher
Aug 16, 2024

Adverum Biotechnologies, Inc. Forecasted to Earn FY2024 Earnings of ($4.07) Per Share (NASDAQ:ADVM) - MarketBeat

Aug 16, 2024
pulisher
Aug 15, 2024

Brokers Offer Predictions for Adverum Biotechnologies, Inc.’s Q3 2024 Earnings (NASDAQ:ADVM) - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Brokers Issue Forecasts for Adverum Biotechnologies, Inc.'s FY2025 Earnings (NASDAQ:ADVM) - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

Adverum Biotechnologies, Inc. to Post FY2025 Earnings of ($4.31) Per Share, Chardan Capital Forecasts (NASDAQ:ADVM) - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Adverum Biotechnologies (NASDAQ:ADVM) Price Target Cut to $40.00 by Analysts at Truist Financial - Defense World

Aug 15, 2024
pulisher
Aug 15, 2024

Adverum Biotechnologies (NASDAQ:ADVM) Upgraded to “Hold” at StockNews.com - Defense World

Aug 15, 2024

Adverum Biotechnologies Inc Azioni (ADVM) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Adverum Biotechnologies Inc Azioni (ADVM) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Leonard Braden Michael
10% Owner
Jul 17 '24
Buy
7.75
135,546
1,049,926
2,101,546
Leonard Braden Michael
10% Owner
Jul 18 '24
Buy
9.11
80,718
735,736
2,182,264
Scopa James Paul
Director
Feb 07 '24
Buy
1.35
100,000
135,000
100,000
Lupher, Jr. Mark L.
Director
Feb 07 '24
Buy
1.35
130,000
175,500
130,000
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Capitalizzazione:     |  Volume (24 ore):